Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neuroendocrine
Pharma
FDA recognizes 'crossover impact' on survival in Cabometyx nod
The FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors after canceling a planned advisory committee meeting.
Angus Liu
Mar 26, 2025 11:03am
FDA cancels adcomm for Cabometyx in neuroendocrine tumors
Jan 10, 2025 9:46am
Exelixis' Cabometyx to face FDA adcomm in neuroendocrine tumors
Nov 27, 2024 11:30am
With trial win, Novartis eyes first-line use for Lutathera
Sep 25, 2023 10:33am
